Insights in Nutrition and Metabolism

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Insights in Nutrition and Metabolism (2023) Volume 7, Issue 5

Short note on epigenetics and cancer: The hidden code of disease.

Sarah Oscar*

Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain

*Corresponding Author:
Sarah Oscar
Department of Biochemistry and Molecular Biology
University of Barcelona
Barcelona, Spain

Received:26-Aug-2023,Manuscript No. AAINM-23-112856; Editor assigned: 29-Aug-2023, PreQC No. AAINM-23-112856 (PQ); Reviewed:12-Sept-2023, QC No. AAINM-23-112856; Revised:18-Sept-2023, Manuscript No. AAINM-23-112856 (R); Published:25-Sept-2023, DOI: 10.35841/aainm- 7.5.166

Citation: Oscar S. Short note on epigenetics and cancer: The hidden code of disease. Insights Nutr Metab. 2023;7(5):166

Visit for more related articles at Insights in Nutrition and Metabolism


Cancer, a complex and multifaceted group of diseases, remains one of the most formidable challenges in the field of medicine. While significant progress has been made in understanding the genetic basis of cancer, there is growing recognition that epigenetic mechanisms play a pivotal role in cancer initiation, progression, and treatment. Epigenetics, the study of heritable changes in gene expression that do not involve alterations to the DNA sequence, provides a crucial framework for comprehending the intricacies of cancer development. In this article, we will explore the intricate relationship between epigenetics and cancer, shedding light on how epigenetic modifications can drive the onset of cancer, influence its behavior, and offer promising avenues for cancer therapy.


To grasp the significance of epigenetics in cancer, it's essential to understand the fundamental concepts of epigenetic regulation. The term "epigenetics" refers to modifications that occur on or around the DNA molecule, as well as to the proteins and RNA molecules that interact with DNA, influencing gene expression without altering the underlying genetic code. These epigenetic modifications serve as a regulatory layer, orchestrating when and to what extent specific genes are activated or silenced. Epigenetic modifications include DNA methylation, histone modifications, and non-coding RNA molecules, all of which contribute to the intricate gene regulatory network. DNA methylation involves the addition of a methyl group to cytosine bases, typically occurring in CpG dinucleotides [1].

These methyl groups can inhibit gene expression by blocking transcription factors and other binding proteins from accessing the DNA. Conversely, histone modifications, such as acetylation, methylation, and phosphorylation, can either activate or repress gene expression by altering the packaging and accessibility of DNA within chromatin. Non-coding RNAs, including microRNAs and long non-coding RNAs, play a crucial role in gene regulation. MicroRNAs can bind to messenger RNA (mRNA) molecules and either degrade them or inhibit their translation into proteins, thus regulating gene expression post-transcriptionally. Long non-coding RNAs can influence gene expression through various mechanisms, such as chromatin remodeling and protein interactions.

Epigenetics and cancer development

Cancer arises from the accumulation of genetic and epigenetic alterations that disrupt the normal control mechanisms of cell growth and division. While genetic mutations are undoubtedly pivotal, epigenetic changes can profoundly influence the development and progression of cancer. Here, we delve into the ways in which epigenetics is intimately connected to various aspects of cancer development.

Epigenetic alterations in cancer genes: Epigenetic modifications can directly impact the expression of key genes involved in cancer. For example, hypermethylation of promoter regions in tumor suppressor genes can lead to their silencing, promoting uncontrolled cell growth. Conversely, hypomethylation in oncogenes can enhance their activity, contributing to tumorigenesis [2].

Global hypomethylation: In contrast to localized hypermethylation of specific genes, cancer cells often exhibit global hypomethylation, which can result in genomic instability. Hypomethylation can lead to the reactivation of transposable elements, causing chromosomal rearrangements and contributing to the overall genetic chaos within cancer cells.

Histone modifications: Aberrant histone modifications are common in cancer. For instance, histone deacetylases (HDACs) can remove acetyl groups from histones, leading to condensed chromatin and gene silencing. Inhibition of HDACs is being explored as a therapeutic strategy to reverse these epigenetic changes in cancer.

MicroRNA dysregulation: Dysregulated microRNAs are frequently observed in cancer. Some microRNAs function as oncogenes, promoting tumor growth, while others act as tumor suppressors by inhibiting cancer-related gene expression. Understanding these microRNA networks is crucial for developing targeted therapies.

Epigenetic plasticity: Cancer cells exhibit a remarkable degree of epigenetic plasticity, allowing them to adapt to changing environments and treatment pressures. This plasticity can lead to therapy resistance and disease progression [3].

Epigenetics as a diagnostic and prognostic tool

The epigenetic landscape of cancer is highly diverse, with distinct epigenetic profiles associated with different cancer types and stages. This heterogeneity provides an opportunity for the development of epigenetic biomarkers that can aid in cancer diagnosis, prognosis, and treatment stratification.

Diagnostic biomarkers: Epigenetic alterations, such as DNA methylation patterns or microRNA expression profiles, can be used to differentiate between cancer and normal tissue. For example, the methylation status of certain genes is used as a diagnostic marker in colorectal cancer.

Prognostic biomarkers: Epigenetic changes can also predict the clinical course of cancer. Certain epigenetic signatures are associated with more aggressive disease and poorer outcomes. Identifying these signatures can help guide treatment decisions.

Predicting treatment response: Epigenetic profiling can assist in predicting how a patient will respond to specific therapies. For instance, DNA methylation patterns can indicate whether a tumor is likely to respond to a particular drug or become resistant [4].

Epigenetic therapies

The unique characteristics of epigenetic modifications have led to the development of novel cancer therapies aimed at reversing or exploiting these alterations. Epigenetic therapies can broadly be categorized into two approaches: epigenetic inhibitors and epigenetic activators .

Epigenetic inhibitors: These drugs target enzymes responsible for adding or removing epigenetic marks. DNA methyltransferase inhibitors (DNMT inhibitors) like 5-azacytidine and histone deacetylase inhibitors (HDAC inhibitors) like vorinostat have been approved for the treatment of certain cancers. These drugs aim to reverse aberrant epigenetic silencing of tumor suppressor genes.

Epigenetic activators: In contrast to inhibitors, epigenetic activators aim to enhance the expression of genes that can suppress cancer growth. Bromodomain inhibitors, for example, target proteins that recognize acetylated histones, thereby promoting the expression of tumor-suppressive genes.

Challenges and future directions

While the promise of epigenetic therapies is undeniable, several challenges and questions remain:

Specificity and off-target effects: Epigenetic therapies can have unintended consequences, affecting both cancer and normal cells. Achieving specificity in targeting epigenetic marks is a significant challenge.

Resistance: Cancer cells often develop resistance to epigenetic therapies. Understanding the mechanisms behind this resistance is essential for improving treatment outcomes.

Combination therapies: The future of cancer treatment may involve combining epigenetic therapies with other treatment modalities, such as immunotherapy or targeted therapies, to maximize therapeutic benefit.

Ethical considerations: As epigenetic editing technologies advance, ethical questions regarding their use in cancer therapy and potential germline editing must be addressed [5].


Epigenetics has revolutionized our understanding of cancer biology, revealing the critical role of epigenetic modifications in cancer development, progression, and treatment. Epigenetic alterations can drive the initiation of cancer, shape its behaviour , and offer innovative therapeutic strategies. As research in this field continues to advance, we can anticipate more precise diagnostic tools, novel epigenetic therapies, and improved outcomes for cancer patients. The epigenetic code may be hidden, but its potential to transform cancer care is becoming increasingly clear.


  1. Sanchez-Gurmaches J, Hung CM, Guertin DA.Physiological roles of long noncoding RNAs: Insight from knockout mice.Trends Cell Biol. 2014;24(10):594-602.
  2. Indexed at, Google Scholar, Cross Ref

  3. Sun H, Huang Z, Sheng W, et al.Emerging roles of long non-coding RNAs in tumor metabolism.J Hematol Oncol. 2018;11:1-6.
  4. Indexed at, Google Scholar, Cross Ref

  5. Sparmann A, Van Lohuizen M.Polycomb silencers control cell fate, development and cancer.Nat Rev Cancer. 2006;6(11):846-56.
  6. Indexed at, Google Scholar,Cross Ref

  7. Hou L, Zhang X, Wang D, et al.Environmental chemical exposures and human epigenetics.Int J Epidemiol. 2012;41(1):79-105.
  8. Indexed at, Google Scholar, Cross Ref

  9. Baumann M, Pontiller J, Ernst W.Structure and basal transcription complex of RNA polymerase II core promoters in the mammalian genome: An overview.Mol Biotechnol. 2010;45:241-7.
  10. Indexed at, Google Scholar, Cross Ref

Get the App